US specialty pharmaceutical company Mallinckrodt (NYSE: MNK) saw its shares rise more than 2% to $86.06 in pre-market trading, after announcing that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular (IBAM).
The total consideration of around $690 million (before tax impacts) consists of about $574 million of up-front consideration, the assumption of around $39 million of long-term obligations, and about $77 million of contingent consideration.
"Mallinckrodt's Nuclear Imaging operation has a long history going back 50 years, and has been a strong cash-generating business over time. Our team has made significant progress in driving profitability over the past few years," said Mark Trudeau, president and chief executive of Mallinckrodt.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze